Overview

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Eisai Inc.